8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 10, 2026·SEC
Rapport Therapeutics, Inc. Common Stock(RAPP)Earnings, Financials & Key Ratios
RAPP•NASDAQ
$39.72
Price updated Jul 7, 2026
AboutRapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$124M-50.9%
- Net Income-$111M-42.4%
- EPS (Diluted)-2.86+24.3%
- ROE-28.22%+49.6%
RAPP Price & Volume
Rapport Therapeutics, Inc. Common Stock (RAPP) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial execution dependency
Key Thesis Takeaways
- Rapport Therapeutics remains a high-risk, clinical-stage biotechnology firm whose valuation is almost entirely dependent on the successful advancement of its RAP-219 program.
- While the company recorded a non-recurring $20.0M revenue event in 2026Q1, the underlying business model continues to face significant pressure from escalating R&D expenditures that reached $32.7M in the same period.
- Investors should monitor the rapid depletion of cash reserves, which fell from $251.4M in 2025Q3 to $78.1M by 2026Q1, as the firm lacks a sustainable commercial product to offset its heavy operational burn.
Verdict Logic
the rapid contraction of cash from $251.4M in 2025Q3 to $78.1M in 2026Q1 suggests an unsustainable burn rate that poses a significant risk of future shareholder dilution.
RAPP Growth Metrics
Rapport Therapeutics, Inc. Common Stock (RAPP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-15.56%
Return on Capital
10 Years-35.9%
5 Years-35.9%
3 Years-36.32%
Last Year-31.29%
RAPP Recent Earnings
Rapport Therapeutics, Inc. Common Stock (RAPP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (75%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.42+25.0%
$0.56
Rev
$20M+166.7%
$8M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.72-10.8%
$0.65
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.71+7.8%
$0.77
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.75+13.8%
$0.87
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.42vs $0.56+25.0% | $20Mvs $8M+166.7% |
| Q2 2026 | Mar 10, 2026 | $0.72vs $0.65-10.8% | — |
| Q4 2025 | Nov 6, 2025 | $0.71vs $0.77+7.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.75vs $0.87+13.8% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Rapport Therapeutics, Inc. Common Stock (RAPP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $39.72 | $1.45B | -13.89 | — | — | -28.22% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — |
Compare RAPP vs Peers
Rapport Therapeutics, Inc. Common Stock (RAPP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RAPP SEC Filings & Documents
Rapport Therapeutics, Inc. Common Stock (RAPP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RAPP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RAPP Frequently Asked Questions
Rapport Therapeutics, Inc. Common Stock (RAPP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Rapport Therapeutics, Inc. Common Stock's revenue?
Rapport Therapeutics, Inc. Common Stock (RAPP) reported $20.0M in revenue for fiscal year 2025.
Is RAPP profitable?
Rapport Therapeutics, Inc. Common Stock (RAPP) reported a net loss of $107.3M for fiscal year 2025.
Dividend & Returns
What is RAPP's return on equity?
Rapport Therapeutics, Inc. Common Stock (RAPP) has a return on equity (ROE) of -28.2%. Negative ROE indicates the company is unprofitable.
What is Rapport Therapeutics, Inc. Common Stock's free cash flow?
Rapport Therapeutics, Inc. Common Stock (RAPP) had negative free cash flow of $80.5M in fiscal year 2025, likely due to heavy capital investments.